Paul Hudson, Sanofi CEO (Romuald Meigneux/Sipa via AP Images)

Sanofi jump­starts ef­fort to sup­ply 30 'essen­tial' drugs to low­er-in­come coun­tries

A week af­ter Sanofi promised to cut in­sulin prices, the phar­ma gi­ant’s non­prof­it unit is of­fer­ing more de­tails on its ef­fort to make the life-sav­ing drug and 29 oth­ers avail­able to 40 low­er-in­come coun­tries.

To­geth­er, the med­i­cines will form what Sanofi calls the Im­pact brand. They cov­er a range of dis­eases, from di­a­betes to car­dio­vas­cu­lar dis­ease to can­cer, and are con­sid­ered es­sen­tial by the World Health Or­ga­ni­za­tion, the com­pa­ny said.

The ef­fort falls un­der Sanofi’s non­prof­it unit Sanofi Glob­al Health, which was launched just last year. Sanofi made the pledge to make 30 drugs avail­able in low­er-in­come coun­tries around the same time.

“Sanofi Glob­al Health aims to im­prove the lives of mil­lions of peo­ple who now can­not get the help they need. Sanofi’s re­newed pur­pose is to chase the mir­a­cles of sci­ence to im­prove peo­ple’s lives. And our quest to make life bet­ter for all peo­ple must in­clude help­ing to pro­vide bet­ter ac­cess to care and qual­i­ty med­i­cines for un­der­served pop­u­la­tions,” CEO Paul Hud­son said in a state­ment.

The type 2 di­a­betes treat­ment gliben­clamide and chemother­a­py ox­ali­platin are al­so on the list, ac­cord­ing to Sanofi.

In ad­di­tion to the med­i­cines, Sanofi is es­tab­lish­ing an Im­pact fund to sup­port star­tups look­ing for sus­tain­able health­care so­lu­tions in un­der­served re­gions by of­fer­ing fi­nanc­ing and tech­ni­cal as­sis­tance. The phar­ma gi­ant is get­ting the ball rolling with $25 mil­lion, ac­cord­ing to a Reuters re­port.

“We know that we can­not do this alone, and so we are build­ing part­ner­ships at glob­al, re­gion­al and lo­cal lev­els that will help to im­prove and es­tab­lish health sys­tems to reach our goal of a health­i­er, more re­silient world,” Jon Fairest, head of Sanofi Glob­al Health, said in the state­ment.

Last Wednes­day, Sanofi an­nounced that it would cut the month­ly price of its in­sulins for unin­sured Amer­i­cans from $99 down to $35. The move fol­lows the House pas­sage of a month­ly cap back in March, which just 12 Re­pub­li­cans sup­port­ed.

This sto­ry has been up­dat­ed to clar­i­fy that Sanofi made its ini­tial pledge last year.

Has the mo­ment fi­nal­ly ar­rived for val­ue-based health­care?

RBC Capital Markets’ Healthcare Technology Analyst, Sean Dodge, spotlights a new breed of tech-enabled providers who are rapidly transforming the way clinicians deliver healthcare, and explores the key question: can this accelerating revolution overturn the US healthcare system?

Key points

Tech-enabled healthcare providers are poised to help the US transition to value, not volume, as the basis for reward.
The move to value-based care has policy momentum, but is risky and complex for clinicians.
Outsourced tech specialists are emerging to provide the required expertise, while healthcare and tech are also converging through M&A.
Value-based care remains in its early stages, but the transition is accelerating and represents a huge addressable market.

No­vo Nordisk re­mains un­der UK scruti­ny as MHRA con­ducts its own re­view in 'in­cred­i­bly rare' case

The UK’s Medicines and Healthcare products Regulatory Agency is now reviewing Novo Nordisk’s marketing violation that resulted in its loss of UK trade group membership last week. Novo Nordisk was suspended on Thursday from the Association of the British Pharmaceutical Industry (ABPI) for two years after an investigation by its regulatory arm found the pharma broke its conduct rules.

MHRA said on Tuesday that its review of the Prescription Medicines Code of Practice Authority (PMCPA) investigation is standard practice. An MHRA spokesperson emphasized in an email to Endpoints News that the situation with Novo Nordisk is “incredibly rare” while also noting ABPI took “swift and proportionate action.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

FTC says patent bat­tle over Parkin­son's drug could have 'sig­nif­i­cant im­pli­ca­tion­s' for pa­tients

The Federal Trade Commission has gotten involved in a patent feud over Supernus’ Parkinson’s drug Apokyn, a case the agency said may have ‘‘significant implications” for patients who rely on the drug.

Sage Chemical won the first generic approval for its Apokyn formulation (also known as apomorphine hydrochloride injection) back in 2022. The non-ergoline dopamine agonist is approved to treat Parkinson’s symptoms during “off episodes,” such as difficulty moving, tremors and intense cramping. However, regulators specified that the approval pertained to the generic drug cartridges only, not the injector pen required for administration.

Growth hor­mone from No­vo Nordisk is in short­age over man­u­fac­tur­ing de­lays

Novo Nordisk’s growth hormone Norditropin is in shortage because of manufacturing delays, according to an FDA site that tracks drug shortages as well as the American Society of Health-System Pharmacists’ shortages list.

The FDA has shortages of the drug listed for its 5, 10, 15 and 30 mg doses, while the pharmacists’ group, also known as ASHP, reported shortages of the same doses, except for the 15 mg version.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

PhRMA calls for more di­verse in­fra­struc­ture up­grades to US emer­gency tri­als frame­work

The White House’s Office of Science and Technology Policy (OSTP) last year sought to find ways to better coordinate large-scale clinical trials in the US — as the UK lead by example during the pandemic — especially for these emergency clinical trials.

The lobbying group PhRMA Tuesday called for more clinical trial diversity in underserved areas, including by making participation less of a burden, and expanding eligibility criteria when appropriate.

Mar­ket­ingRx roundup: What could a US Tik­Tok ban mean for phar­ma? Pfiz­er, Lil­ly lead phar­ma March Mad­ness ad­ver­tis­ers

Just as pharma marketers finally make moves into TikTok, the threat of a US ban on the social media channel is now looming. Already banned on federal employee phones by an initial Congressional act, more bills and maybe bans are on the way. With rare bipartisan agreement, lawmakers have introduced legislation that would give the US president the power to ban TikTok (although not mentioned by name) and other foreign-owned technology platforms that represent a security threat to the US.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Chat­G­PT with phar­ma da­ta de­buts for med­ical meet­ings, be­gin­ning with AACR

What do you get when you combine ChatGPT generative AI technology with specific pharma and clinical datasets? A time-saving tool that can answer questions about medical conference abstracts and clinical findings in seconds in one new application from ZoomRx called FermaGPT.

ZoomRx is debuting a public version of its generative AI product specifically for medical conferences beginning this week for the upcoming American Association for Cancer Research (AACR) annual meeting that runs April 14-19.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 163,200+ biopharma pros reading Endpoints daily — and it's free.

Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)

What kind of PhI­Ib da­ta is worth $4B cash? Take­da’s Andy Plump has some thoughts on that

A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it had already taken a deep dive on the solid Phase IIb data Nimbus had assembled from its dose-ranging study in psoriasis.

Now, it’s rolling that data out, eager to demonstrate what inspired the global biopharma to go long in a neighboring, but new, disease arena for the pipeline. And the most avid students of the numbers will likely be at Bristol Myers Squibb, who will have a multi-year head start on pioneering the TYK2 space with Sotyktu (deucravacitinib) as Takeda makes its lunge for best-in-class status.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

European Commissioner for Health Stella Kyriakides (AP Photo/Francisco Seco, Pool)

One fi­nal push: EU phar­ma in­dus­try group de­mands com­pe­ti­tion check on in­com­ing leg­isla­tive over­haul

The Brussels-based European Federation of Pharmaceutical Industries and Associations (EFPIA) this morning called on the European Commission to ensure that it adequately assesses how its re-writing of the 20+-year-old pharma legislation, which is due to be released before the end of the month, damages the competitiveness of the pharma industry.

EFPIA’s opposition to the changes has lingered since the beginning, and its latest estimate is that the rewritten legislation could cost the industry €640 million ($688 million).